Investors
Creating value for stakeholders
We are an established, commercial-stage diagnostics company.
We are an established, commercial-stage diagnostics company with over 30 years’ experience of manufacturing and supplying the conventional reagent products used for blood grouping within the $3.4 billion global transfusion diagnostics market.
Our proprietary technology platform, MosaiQ, is continually been developed and enhanced to better address the comprehensive needs of this large and established market. We believe MosaiQ has the potential to be a transformative technology that significantly reduces the cost of blood grouping in both donor and patient-testing environments.
Investors
4:00 PM EDT • Oct 27, 2020
QTNT
4.57USD
-0.22%
Contact
Peter Buhler, Chief Financial Officer
IR@quotientbd.com
3 Months
6 Months
12 Months
Quotient Ltd
$
Events & presentations
Quotient Limited to Report Second Quarter 2021 Financial Results and Host Conference Call
Quotient Limited to Publish Quarterly Investor Presentation
Press releases
Quotient Limited Announces Receipt of U.S. FDA Emergency Use Authorization (EUA) for MosaiQ COVID-19 Antibody Test
Our reagents by Quotient
Alba by Quotient. Experience. Expertise. Value.
These are just some of the qualities that set us apart from the competition. You can have peace of mind using our products, which have been time-tested for more than 30 years.